Search results | Roche

Reports

Partnering Agreements with Roche

This report provides all the information you require to better understand Roche and its partnering interests and activities over the past seven years.

Insights

Roche drops business merger rumors with Chugai Pharmaceutical

Roche had business merger rumors to buy Tokyo-based Chugai Pharmaceutical Co., Ltd. appear to be tabled for now. Sources in Roche indicated the company was focused on its $8.3 billion acquisition of California-based InterMune Inc.

Roche to buy 40% stake in Chugai Pharma

Roche Holding is in talks to buy the almost 40 percent of Chugai Pharmaceutical that it doesn’t already own to gain full control of its Japanese partner for oncology and arthritis drugs, according to people familiar with the matter.

Roche

Roche is a top pharmaceutical/biotechnology company based in Basel, Switzerland

Roche CEO may seek rare disease deals

Swiss drugmaker Roche Holding AG would not exclude a move into treatments for rare diseases, its CEO said on Wednesday, even if this represented very small numbers of patients

Roche and Novartis in merger and acquisition talks?

Merger and acquisition rumor mill :Roche Holding AG  founding families want the Swiss drugmaker to stay independent, Chief Executive Officer Severin Schwan said, squelching speculation that circulated since a board member at crosstown rival Novartis AG (NOVN) said last month a merger could make sense

Roche seeking for potential Alexion bid: Biotech Rumor mill

Biotech Rumor mill: Alexion Pharmaceuticals , the big biotech company, whose blood-disease treatment is among the world’s most expensive medicines, engaged Goldman Sachs Group Inc. as an adviser as it prepares for a possible takeover offer from Roche Holding AG (ROG), said people with knowledge of the matter

Biotech rumor mill: Alexion valuation could choke any Roche bid

Buying Alexion Pharmaceuticals would help Roche make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss drugmaker is ultimately not willing to pay, according to the biotech rumor mill.

Big biotech rumor mill: Novartis’ Vasella exit opens door to Roche stake sale

The big biotech rumor mill gives idea that a changing of the guard at Switzerland’s two biggest drugmakers means that Novartis may finally sell its multi-billion-dollar stake in cross-town rival Roche, potentially unlocking value for both sets of shareholders.

Partnering with Roche: Think Roche, Think Partnering

Roche is a top pharma company active in partnering, licensing and M&A in pharmaceuticals and biotechology

Roche: M&A activity 2005-2013

Roche has announced 21 M&A deals since 2005, with the lead deals being the acquisition of Genentech and Ventana Medical Systems

Events

Sorry, your search returned no results.


Deals

Roche and 4D Molecular partner for AAV vectors

4D Molecular Therapeutics announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors

Roche and Curevac partner for IDO1 and TDO inhibitors

Curadev Pharma has entered into a research collaboration and license agreement with Roche for development and commercialization of IDO1 and TDO inhibitors

Roche acquires Capp Medical

Roche has acquired CAPP Medical, a genomics research company

Roche and Celldex in varlilumab and MPDL3280A combo pact

Celldex Therapeutics has entered into a clinical trial collaboration with Roche

Roche acquires Signature Diagnostics for access to translational oncology and genomics

Roche announced the acquisition of Signature Diagnostics

Roche acquires Trophos for $540 million

Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France

Roche licenses OP0595 from Meiji and Fedora

Roche, Meiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595

Roche and Foundation Medicine in personalized meds for cancer pact

Foundation Medicine and Roche enter into a broad strategic collaboration to further advance Foundation Medicine’s market-leading position in molecular information and genomic analysis

Roche acquires majority stake in Foundation Medicine

Roche will commence a tender offer at a per share price of USD 50, which, when combined with Roche’s direct investment in Foundation Medicine

Roche acquires Bina and Dutalys in festive shopping spree

Roche has agreed to acquire Dutalys and Bino Technologies in a end of year acquisition push